XASEPTN
Market cap19mUSD
Dec 24, Last price
0.98USD
1D
0.71%
1Q
1.68%
Jan 2017
-92.26%
Name
Palatin Technologies Inc
Chart & Performance
Profile
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | ||||||||||
Revenues | 4,490 -7.49% | 4,854 230.53% | 1,468 -878.62% | |||||||
Cost of revenue | 22,498 | 23,049 | 21,545 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (18,008) | (18,195) | (20,077) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | (4,675) | (390) | ||||||||
Tax Rate | ||||||||||
NOPAT | (18,008) | (13,520) | (19,686) | |||||||
Net income | (29,736) 7.97% | (27,542) -23.08% | (35,808) 6.67% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 14,666 | 10,143 | (205) | |||||||
BB yield | -51.17% | -44.35% | 0.31% | |||||||
Debt | ||||||||||
Debt current | 853 | 921 | 472 | |||||||
Long-term debt | 754 | 1,641 | 1,836 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 1,032 | 2,083 | 2,861 | |||||||
Net debt | (7,920) | (8,420) | (27,631) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (31,461) | (28,419) | (29,923) | |||||||
CAPEX | (43) | (434) | (261) | |||||||
Cash from investing activities | 12,450 | (3,427) | (261) | |||||||
Cash from financing activities | 20,549 | 9,896 | 18 | |||||||
FCF | (17,363) | (13,664) | (19,772) | |||||||
Balance | ||||||||||
Cash | 9,527 | 10,982 | 29,939 | |||||||
Long term investments | ||||||||||
Excess cash | 9,303 | 10,740 | 29,866 | |||||||
Stockholders' equity | (441,587) | (397,596) | (387,901) | |||||||
Invested Capital | 443,525 | 401,325 | 408,184 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 14,697 | 10,890 | 9,544 | |||||||
Price | 1.95 -7.14% | 2.10 -70.06% | 7.02 -54.00% | |||||||
Market cap | 28,659 25.32% | 22,869 -65.84% | 66,949 -53.62% | |||||||
EV | 20,739 | 32,388 | 39,318 | |||||||
EBITDA | (17,669) | (17,907) | (19,950) | |||||||
EV/EBITDA | ||||||||||
Interest | 17 | 20 | 30 | |||||||
Interest/NOPBT |